1. Lan Li, Fadi S, Braiteh FS et al.: Liposome encapsulated curcumin, in vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis.

Cancer 2005 104:1322-1331

2. Lan Li, Bilal Ahmed,Kapil Mehta et al.: Liposomal curcumin with and without oxaloplatin: effects on cell growth, apoptosis and angiogenesis in colorectal cancer.

Molecular Cancer Therapeutics. 2007 6:1276-1282

3. Savita Bisht, Georg Feldman, Scheetal Soni et al.: Polymeric nanoparticle encapsulated curcumin nanocurcumin: a novel strategy for human cancer therapy.

J Nanobiotechnology 2007 5:3

4. Claire M Mach, Lata Matthew, Scott A Mosley, Lawrence Helson et al.: Determination of minimum effective dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer.

Am Coll Clin Pharm.Annual meeting. 2008 Louisville KY. Presentation.

5. Clair M Mach, Lata Mathew, Scott A Mosley, et al.: Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.

Journal of Anticancer Research. 2009 29: 1895-1900

6. Clair M Mach, J.H.Chen, Sa Mosley et al. Evaluation of Curcumin Cytochrome p450 metabolism.

Hematology Oncology Pharmacy Association(HOPA) June 17-20 ,2009. Abstract. Manuscript submitted J. Anticancer Research. 2010 in press.

7. Vishwanatha JK.: Biodegradable Nanoparticles for Cancer Therapy.

2nd Annual Unither Nanomedical and Telemedical Conference. Oreford Quebec, Canada Abstract presentation Feb 24-27 2009

8. MukerjeeA, and JK Vishwanatha: Formulation, Characterization and evaluation of Curcumin loaded PLGA nanospheres for cancer therapy.

Journal of Anticancer Research 2009 29:3867-3876

9. Judith A Smith, Lata Mathew, MS Claire, K Santiago, L.Helson: Development of Liposomal curcumin as a new potential anticancer agent.

MD Anderson Cancer Center and Signpath Pharma. AACR–EORTC-NCI 2009. Abstract and presentation Nov 18

10. Mukerjee A, Ranjan AP, Helson L et al: Formulation, Characterization and Evaluation of Annexin A2-conjugated curcumin loaded nanospheres as a targeted drug carrier system for breast cancer therapy.

Proc.10thUS-Japan Symposium on Drug Delivery Systems. 2009 Maui, Hawaii. Ab no. 1468

11. Ranjan AP, Mukerjee A, JK Vishwanatha. Optimization of curcumin loaded PLGA nanoparticle-formulation using central composite design for cancer therapy.

Proc. 10thUS-Japan Symposium on Drug Delivery Systems. 2009 Maui, Hawaii. Ab no 1526

12. Mukerjee A, Luchowski R, Ranjan et al.: Enhanced Fluorescence of curcumin on plasmonic platforms.

Current Pharmaceutical Biotechnology. 2010 11:223-228

13. Lim KJ, Maitra A, Bisht S et al.: Using Nanocurcumin to treat Medulloblastoma and Glioblastoma.

AACR Annual meeting Ab no.4440, 2010

14. Claire M Mach, Jing Hong Chen, Scott A Mosley: Evaluation of Liposomal Curcumin Cytochrome P450 Metabolism.

Anticancer Research 2010 30:811-814

15. Mukerjee A, Sorenson T Thomas J et al.: Spectroscopic properties of curcumin, orientation of transition moments.

J Physical Chemistry 2010 114:12679-12684

16. Bisht S,Mizuma M,Feldman G. et al.: Systemic Administration of Polymeric nanoparticle –encapsulated Curcumin(Nanocurc®) blocks tumor growth and metastases in preclinical models of Pancreatic Cancer.

Mol Canc Ther. 2010 9: 2255-2264

17. Thamake S I, Iraut Sf, Ranjan AP,Gryczynski Z,and J K Vishwanatha.: Surface Functionalization of PLGA nanoparticles by non-covalent insertion of homo-bifunctional spacer for active targeting in cancer therapy.

J Alzheimers Disease. 2011 Jan 1;23(1):61-77

18. Ray B, Bisht S, Maitra A, Maitra A, Lahiri, DK. Neuroprotective and Neurorescue Effects of a Novel Polymeric Nanoparticle Formulation of Curcumin (NanoCurc™) in the Neuronal Cell Culture and Animal Model: Implications for Alzheimer’s disease.

Mol Canc Ther. 2010 9: 2255-2264

19. Helson L. Chiu S: Curcumin Formulations Brain Distribution.

Presentation to MJFF for Parkinson’s disease NYC Sept 21, 2010.

20. Chiu SS, Lui E, Majeed M, Vishwanatha JK, Ranjan A, Maitra A, Dipanker P, Smith JA ,Helson L:Differential distribution of intravenous curcumin formulations in the rat brain.

Mol Canc Ther. 2010 9: 2255-2264

20a. Yin-Meng Tsai, Chao-Feng Chien, Lie-Chwen Lin,Tung-Hu Tsai: Curcumin and its nano-formulation:The kinetics of tissue distribution and blood-brain barrier penetration.

International Journal of Pharmaceutics, 2011 June 24th.

21. Balmiki R, Bisht S, Maitra A et al. Neuroprotective and Neurorescue effects of a Novel Polymeric Nanoparticle Formulation of curcumin (NanoCurc®) in the Neuronal cell culture and Animal Model: Implications for Alzheimer’s disease.

J Alzheimer’s Dis. 2011 23:61-77

22. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG: A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenecity, and stem-like fraction in malignant brain tumors.

Cancer Biology and Therapy 2011, 11(5): 1-10

22a. Tuttle S, Hertan L, Katz JS: Indian gold treating cancer in the age of nano.

Cancer Biology and Therapy, 2011, 11(5): 474-476 (a review of #22)

23. Savita Bisht, Mehtab A Khan, Mena Bekhit, Haibo Bai, Toby Cornish, Masamichi Mizuma, Michelle A Rudek, Ming Zhao, Amarnath Maitra, Balmiki Ray, Debomoy Lahiri, Anirban Maitra, and Robert A Anders. A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation.

Laboratory Investigation (2011), 1–13

24. Lawrence Helson, George Shopp, Annie Bouchard, Muhammad Majeed. Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current.

Journal of Receptor, Ligand and Channel Research, 2012

25. LAWRENCE HELSON, GORDON BOLGER, MUHAMMED MAJEED, BRIGITTA VCELAR, KRESIMIR PUCAJ, and DHARMENDR MATABUDUL Infusion Pharmacokinetics of Lipocurc™ (Liposomal Curcumin) and its Metabolite Tetrahydrocurcumin in Beagle dogs.

Anticancer Res, 2012

26. Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson and Jamboor K Vishwanatha Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy.

Journal of Nanobiotechnology, 2012

27. DHARMENDR MATABUDUL, KRESIMIR PUCAJ, GORDON BOLGER, BRIGITTA VCELAR, MUHAMMED MAJEED and LAWRENCE HELSON: Tissue Distribution of (LipocurcTM) Liposomal Curcumin and Tetrahydrocurcumin Following Two- and Eight-hour Infusions in Beagle Dogs.

Anticancer Res, 2012

28. Simon Chiu, Kristen J. Terpstra ,Yves Bureau,Jirui Hou, Hana Raheb, Zack Cernvosky, Vladimir Badmeav7 , John Copen; Mariwan Husni, Michael Woodbury: Liposomal-formulated curcumin[ LipocurcTM ] targeting HDAC (Histone Deacetylase ) , prevents apoptosis and improves motor deficits in Park 7 (DJ-1)- Knockout rat model of Parkinson’s disease : implications for Epigenetics-based Nanotechnology-driven Drug Platform.

29. Zou P, Helson L, Maitra A, Stern ST, McNeil SE Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.

30. Poster “Safety and Pharamacokinetics of Liposomal Curcumin in Healthy Subjects: A Randomized Placebo_Controlled Double Blind First-in-human Study”

31. Rajan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis.

Anticancer Res, 2013 Sep; 33(9):3603-9

32. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso D, Zhao M, Rudek M, Stearns V, Maitra A, Sukumar S. Intraductal Administration of a Polymeric Nanoparticle Formulation of Curcumin (NanoCurc) Significantly Attenuates Incidence of Mammary Tumors in a Rodent Chemical Carcinogenesis Model Implications for breast cancer chemoprevention in at-risk populations.

Carcinogenesis. 2012 Jul 25. [Epub ahead of print]

33. Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A, Maitra A. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Oncotarget. 2012 Jun;3(6):640-50.

34. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.

Curr Drug Discov Technol. 2009; 6:192-9.

35. Dr. Anirban Maitra, Dr Lawrence Helson Characterization of Nanocurcumin NCL 201304A

36. Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M. Effect of liposomal curcumin on red blood cells in vitro.

Anticancer Res. 2013 Sep;33(9):3629-34

37. Amalendu P. Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha. University of North Texas Health Science Center, Fort Worth, TX. Targeted multifunctional lipid-PLGA hybrid nanosystems for metastatic breast cancer imaging and therapy.

April 08, 2014

38. Shopp GM, Helson L, Bouchard A, Salvail D, Majeed M.Liposomes Ameliorate Crizotinib- and Nilotinib-induced Inhibition of the Cardiac IKr Channel and QTc Prolongation.

September 2014

39. Increased risk of Torsades de Pointes in streptozotocin-induced diabetic rats. Annie Bouchard*, Marie-Claude Benoit*, Sabrina Baillargeon*, Laurence Helson, George Shopp, Dany Salvail*

November 2014

40. Use of nanocurcumin to inhibit proliferation and metastases of hepatocellular carcinoma via NF-κB mediated matrix metalloproteinase-9 downregulation. Author(s): Yang Xu, Bo Hu, Robert Anders, Anirban Maitra, Jia Fan; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Cancer Institute, Fudan University, Shanghai, China; The Johns Hopkins Hospital, Baltimore, MD; Johns Hopkins Hospital, Baltimore, MD

J Clin Oncol 31, 2013 (suppl; abstr e22103)

41. Safety, tolerability and pharmacokinetics of liposomal curcumin (LipocurcTM) in healthy humans. Angela Storka1, Brigitta Vcelar2, Uros Klickovic1, Ghazaleh Gouya1, Stefan Weisshaar1, Stefan Aschauer1, Gordon Bolger4, Lawrence Helson3, and Michael Wolzt1

42. Curcumin Suppression of Cytokine Release and Cytokine Storm. A Potential Therapy for Patients with Ebola and Other Severe Viral Infections. PETER P. SORDILLO and LAWRENCE HELSON

43. Use of an Unconventional Approach to Boost Sensitivity and Improve Chromatography for Quantifying Curcumin and Tetrahydrocurcumin by LC-MS/MS.Aimin Tan; Yanxin Wu; Molly Wong; Albert Licollari; Gordon Bolger; John C. Fanaras; George Shopp; Lawrence Helson

44. Curcumin and Cancer Stem Cells: Curcumin Has Asymmetrical Effects on Cancer and Normal Stem Cells. Peter P. Sordillo and Lawrence Helson. Anticancer Res. 2015 Feb;35(2):599-614.

Anticancer Res. 2015 Feb;35(2):599-614.

45. Curcumin (diferuloylmethane) Delivery Methods: A Review Helson, L

46. Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson and Jamboor K Vishwanatha

47. Poster “Liposomal curcumin (LipocurcTM) and in vitro/in vivosurrogates for cytokine storm associated with uncontrolled EBOLA infection.”

48. Abstract Effects of free curcumin and curcumin-liposomes (LipocurcTM) on pro-inflammatory cytokine expression in synovial fibroblasts and macrophages. Lukas Gober, Silvia Löbsch, Lawrence Helson, Andreas Wagner, Günter Steiner, Burkhard Klösch

49. Poster “Utilizing Drug-Lipid Membrane Partitioning: Novel, highly efficient and scalable loading of poorly water soluble drugs into the lipid membranes of preformed liposomes.” Ehsan Suleiman, Andreas Wagner, Yvonne Perrie

50. “Bifunctional role of pro-inflammatory cytokines after traumatic brain injury” Peter P. Sordillo, Laura A. Sordillo & Lawrence Helson

51. “The Prolonged QT Interval: Role of Pro-inflammatory
Cytokines, Reactive Oxygen Species and the
Ceramide and Sphingosine-1 Phosphate Pathways”
PETER P. SORDILLO, DIANA C. SORDILLO and LAWRENCE HELSON

52. “Sphingosine Kinase Inhibitors as Maintenance Therapy of
Glioblastoma After Ceramide-Induced Response”
LAURA A. SORDILLO, PETER P. SORDILLO and LAWRENCE HELSON

53. “The Kynurenine Pathway: A Primary Resistance
Mechanism in Patients with Glioblastoma”
PETER P. SORDILLO, LAURA A. SORDILLO and LAWRENCE HELSON

54. “Curcumin for the Treatment of Glioblastoma”
LAURA A. SORDILLO, PETER P. SORDILLO and LAWRENCE HELSON

55. “Distribution of Curcumin and THC in Peripheral
Blood Mononuclear Cells Isolated from Healthy
Individuals and Patients with Chronic Lymphocytic
Leukemia”GORDON T. BOLGER, ALBERT LICOLLARI, AIMIN TAN, RICHARD GREIL, LISA PLEYER, BRIGITTA VCELAR, MUHAMMAD MAJEED and PETER SORDILLO

56. “LPS-induced cytokine storm produces QTc prolongation which can be prevented by an anti-inflammatory compound.” Annie Bouchard, Peter Sordillo, Lawrence Helson, Sabrina Baillargeon, George Shopp, Walt Shaw, and Dany Salvail